2023 Was a tricky 12 months with the biopharma business, with various corporations downsizing and restructuring their workforces to stay afloat. You'll find indications of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences business from the latter A part of 2023 and also have https://sites.google.com/view/bio-sites/blog